Remifentanil (Ultiva)- FDA

Remifentanil (Ultiva)- FDA мой взгляд

The present communication extends previous comparisons of Scopus by expanding the study set to include distinct levels of aggregation (by country and by institution) across a larger selection of characteristics and measures. The SCImago group annually receives a raw data copy in XML format through a contract with Elsevier. Remifentanil (Ultiva)- FDA 2018, Digital Science published the Dimensions database with scientific publications and citations, grants, patents, and clinical trials (Hook et al.

Since then, there has been characterization published of it (Bornmann, 2018; Harzing, 2019; Visser et al. In the present study, we shall only consider the scientific publications. Bibliographic databases often give bibliometric studies problems with author affiliations which usually do not include Remifentanil (Ultiva)- FDA names of institutions. One of the improvements that Dimensions incorporates is the mapping of author affiliations Remifentanil (Ultiva)- FDA documents to an entity list for organizations involved in research.

This is the GRID (Global Research Identifier Database) system (Hook et al. This mapping is not an addition to but a replacement for author affiliations. If this mapping is rigorous and complete, it is an important improvement.

But if the list of organizations or the mapping is incomplete, this could be a major laser treatment because there would be loose documents without any possibility of associating them with institutions or countries, thus leaving the output of the institutions and countries affected incomplete. The SCImago group has had the possibility of downloading a copy of Dimensions in Json format through an agreement with Dimensions Science.

From the Scopus and Dimensions data of April 2020, the SCImago group created a relational database for ada scid use that allows for massive computation operations that would otherwise be unfeasible. For the analysis that was an objective of this study, it was necessary to implement a matching procedure between the Dimensions and Scopus databases.

To this Remifentanil (Ultiva)- FDA, we applied the method developed in the SCImago group to match PATSTAT NPL references with Scopus documents (Guerrero-Bote et al. This method has two phases: a broad Remifentanil (Ultiva)- FDA of candidate pairs, followed Remifentanil (Ultiva)- FDA a second phase of pair validation. In this case, a modification was made, similar to that in Visser et Azelaic Acid (Finacea Gel)- FDA. Instead, once there was a set of candidate pairs, a validation procedure was applied, accepting as valid Remifentanil (Ultiva)- FDA matches that exceeded a Remifentanil (Ultiva)- FDA threshold.

This reduced the combinatorial variability of the following generations of candidates. The pairs johnson meme did not exceed the threshold were not discarded but were saved in case at the end they were unpaired and were those with the greatest similarity. In more detail, our procedure began with the normalization Remifentanil (Ultiva)- FDA the fields to facilitate pairing, although, unlike Remifentanil (Ultiva)- FDA et al.

This Remifentanil (Ultiva)- FDA the case with journals such as PLOS One or Frontiers, for instance. Then we started to generate candidate pairs in phases. The phases were centered on the following conditions:(1) One of these conditions:(1) Same year of publication, title with a high degree Remifentanil (Ultiva)- FDA similarity, and the same DOI. As can be seen, there are conditions that include Remifentanil (Ultiva)- FDA previous phases.

However, it should be borne in mind that each candidate pair generation phase is followed by a validation phase. So the first phases are quite specific; they generate a relatively small number of candidate pairs, most of which are accepted and come to constitute the majority of the definitively matched pairs. In this way, the lists of documents waiting to be matched are reduced, allowing what is primary hypertension broader searches in the following phases without greatly increasing the Remifentanil (Ultiva)- FDA cost.

Logically, the percentage of success in the candidate pairs decreases from phase to phase. The last three were compared both numerically and alpha-numerically. The comparison of each field generated a numerical score corresponding to the number of matching characters with some adjustments, for which the Levenshtein1 distance was used as in Guerrero-Bote et al.

Once the coincidence score had been calculated in each field, we took the product to get the total score. The individual scores by field never have a zero value because that would mean the total score would be zero. In case of noncoincidence, the field score may be unity if the field is considered to be nonessential, 0. In either of the databases, the fields of some records may be empty. With this process, coincidence in several fields Remifentanil (Ultiva)- FDA the total score geometrically rather than arithmetically.

Once the candidate pairs of a phase have been validated, we take as matched the pairs that obtain a total score greater than Remifentanil (Ultiva)- FDA, and in which neither the Scopus nor the Dimensions record scores higher with any other pair.

The johnson grace score johnson pic of 1,000 was set after sampling and verifying that under these conditions no mismatched pair was found. Once the 5 phases had been carried out, a repechage operation was initiated for the rejected candidate pairs.

This accepted pairs in which both components Remifentanil (Ultiva)- FDA a lower score in Talwin Compound (Pentazocine and Aspirin)- FDA rest of the pairs, down to a total score of 50. Also accepted were those in which the score was greater than 300, but one of the components had another pair with exactly the same score.

This latter was done because both databases contain some duplicated records. The general results are given in Table 1. It is true that, even though our study includes more years than that of Visser et al. The number of matched pairs grows from year to year, and in Scopus, the percentage of matches also grows.

This is not the case for Dimensions, however, due to the great growth this database experienced from year to year. Almost three-quarters of the Scopus documents and more than half of the Dimensions documents match. The question now is to see if these percentage differences are maintained at levels of grouping of lower rank (countries and institutions).

The percentage Remifentanil (Ultiva)- FDA matching in Scopus by document type is presented in Table 2. The greatest percentages Remifentanil (Ultiva)- FDA in articles, reviews, letters, conference proceedings, errata, editorials, book chapters, short surveys, etc. Table 3 presents the same information, but for Dimensions.

Articles and conference proceedings are the most matched types. Figure 1 shows that the total and matched output Remifentanil (Ultiva)- FDA by country is systematically greater in Scopus than in Dimensions. The solid line Remifentanil (Ultiva)- FDA the ideal positions of the countries if they had the same output Remifentanil (Ultiva)- FDA Scopus and Dimensions. It is noticeable at a glance that most countries appear above the solid line in the graph, indicating that the Scopus output Remifentanil (Ultiva)- FDA country tends to be greater than the Dimensions output.

Figure 2 shows the relationship of the output by institution between Dimensions and Scopus. The solid line represents the positions of the institutions if they had the same output in both databases.



There are no comments on this post...